Aceclofenac-loaded chondroitin sulfate conjugated SLNs for effective management of osteoarthritis

References

• Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone 2012;51:249–57
   PubMed Web of Science ®Google Scholar
• Mandl LA. Epidemiology of osteoarthritis: a companion to rheumatology. Philadelphia (PA): Mosby, Inc. 2007:1–14
   Google Scholar
• Muller RH, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77
   PubMed Web of Science ®Google Scholar
• Muller RH. Zetapotential und Partikelladung in der Laborpraxis. APV paperback series. vol. 37. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1996
   Google Scholar
• Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Contr Rel 2012;163:34–45
   PubMed Web of Science ®Google Scholar
• Muller RH, Maaben S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996;4:161–70
   PubMed Web of Science ®Google Scholar
• Muller RH, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite-loaded polylactide, polylacttide/glycolide particles and solid lipid nanoparticles. Int J Pharm 1996;138:85–94
   Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71–7
   PubMed Web of Science ®Google Scholar
• Souto EB, Muller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005;22:501–10
   PubMed Web of Science ®Google Scholar
• Periyasamy PC, Leijten JC, Dijkstra PJ, et al. Nanomaterials for the local and targeted delivery of osteoarthritis drugs. J Nanomat 2012;2012: 673968
   Google Scholar
• Ryuta Y, Shinichi K, Takeshi M, Norimasa K. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 1997;329:181–7
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257–72
   PubMed Web of Science ®Google Scholar
• Hidekazu T, Yasushi A, Naomi Y, et al. Annexin 6 is a putative cell surface receptor for chondroitin sulfate chains. J Cell Sci 2002;115:3309–18
   PubMed Web of Science ®Google Scholar
• Pecchi E, Priam S, Mladenovic Z, et al. A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts. Osteoarth Cart 2012;20:127–35
   PubMed Web of Science ®Google Scholar
• Rambaruth ND, Dwek MV. Cell surface glycan-lectin interactions in tumor metastasis. Acta Histochem 2011;113:591–600
   Google Scholar
• Jain S, Jain S, Khare P, et al. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Del 2010;17:443–51
   PubMed Web of Science ®Google Scholar
• Mahor A, Sharma A, Gupta Y, Jain SK. Body distribution and stability studies on mitoxantrone loaded solid lipid nanoparticles conjugated with concanavalin A. Int J Pharm Sci 2010;2:39–42
   Google Scholar
• Bagari R, Bansal D, Gulbake A, et al. Chondroitin sulfate functionalized liposomes for solid tumor targeting. J Drug Target 2011;19:251–7
   PubMed Web of Science ®Google Scholar
• Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem 1978;90:809–15
   PubMed Web of Science ®Google Scholar
• Venkateswarlu V, Kopparam M. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004;95:627–38
   PubMed Web of Science ®Google Scholar
• Musmade P, Subramanian G, Srinivasan K. High performance liquid chromatography and pharmacokinetics of aceclofenac in rats. Anal Chem Acta 2007;585:103–9
   PubMed Web of Science ®Google Scholar
• Starowicz K, Vincenzo DM. Non-psychotropic analgesic drugs from the endocannabinoid system: “magic bullet” or “multiple-target” strategies? Eur J Pharmacol 2013;716:41–53
   PubMed Web of Science ®Google Scholar
• Jeremy J, Hammoudi T, Bratt-Leal AM, et al. Development of nano- and microscale chondroitin sulfate particles for controlled growth factor delivery. Acta Biomater 2011;7:986–95
   PubMed Web of Science ®Google Scholar
• Ponedelkina IY, Odinokov VN, Lukina ES, Dzhemilev UM. Conjugation of chondroitin sulfates with amines. Russ J Bioorg Chem 2008;34:632–7
   Google Scholar
• Freitas C, Muller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm 1998;168:221–9
   Web of Science ®Google Scholar
• Yuan H, Miao J, Du YZ, You J. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008;348:137–45
   PubMed Web of Science ®Google Scholar
• Janusz M, Bendele A, Brown K. Induction of osteoarthritis in the rat by surgical tear of the meniscus: inhibition of joint damage by a matrix metalloproteinase inhibitor. Osteoarth Cart 2002;10:785–91
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Kawashima H, Tanaka T, Hirose M. CD44 binds a chondroitin sulfate proteoglycan, aggrecan. Int Immunol 2001;13:359–66
   PubMed Web of Science ®Google Scholar